NASIMA SZCZESNY: Open Payments
NPI 1851921431 · OKEMOS, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,945 in 106 payments from 21 companies in 2025. Trend: 2023 $568 · 2024 $1,137 · 2025 $1,945
Food & beverage: $1,945
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $325 |
| Novo Nordisk Inc | 18 | $304 |
| Axsome Therapeutics, Inc. | 9 | $269 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 18 | $233 |
| PFIZER INC. | 15 | $192 |
| Otsuka America Pharmaceutical, Inc. | 8 | $152 |
| Lilly USA, LLC | 3 | $68 |
| Amgen Inc. | 3 | $53 |
| Biogen, Inc. | 2 | $52 |
| Antares Pharma, Inc. | 3 | $47 |
Products named: CAPLYTA, Wegovy, QULIPTA, REXULTI, Auvelity, NURTEC ODT, Symbravo, VRAYLAR.
Industry payments across MI — which companies pay providers there.
